Stopping germs from ganging up on humansNovember 20, 2008Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson. John W. Pepper proposes a new strategy in the arms race between humans and germs-- targeting the teamwork within gangs of germs. Most drugs used to fight infections kill the vulnerable disease-causing organisms, or pathogens, but the resistant ones survive. The next generation will all carry the resistance to the drug. "We know that the pathogen is causing the disease. The obvious solution is to kill the pathogen. It makes perfect sense, and that's what we've always done," said Pepper, a UA assistant professor of ecology and evolutionary biology. "But there's one big flaw with that -- and that is the evolution of resistance." Pepper's mathematical models show it takes longer for a group of cells to develop resistance to drugs that attack the teamwork factors than for individual cells to become resistant to a traditional antibiotic. He advocates developing drugs that attack the pathogens' methods and resources for cooperation. Pepper said once the teamwork is disrupted, the immune system can combat any remaining infection. He said this new approach will work against "old enemies and some new ones" that are becoming drug resistant, including methicillin-resistant Staphylococcus aureus bacteria (MRSA), HIV, malaria, tuberculosis, avian influenza and cancer. Pepper is also a member of UA's BIO5 Institute and an external professor at the Sante Fe Institute in New Mexico. His paper, "Defeating Pathogen Drug Resistance: Guidance from Evolutionary Theory," is scheduled for publication in the December issue of the journal Evolution. Pepper began investigating cooperation by studying parrots and dolphins. Now he studies cooperation among individual cells. Most cells such as a bacterium produce materials that ensure their own survival and maintain infections by helping both themselves and their fellows. For pathogens, there's strength in numbers. As they form groups, they become a greater threat. For example, MRSA produce more than 50 resources essential for the group. Where others may see an unconquerable defense, Pepper sees 50 opportunities. The number and type of materials produced within a gang of pathogens varies. However, if one material is eliminated, none of the cells will survive. Neither will the infection. He is currently collaborating with cancer biologists to attack chemicals that allow cancer cells to gang up on normal cells. One type of chemical, the angiogenesis factor, is secreted by cancerous cells to stimulate the growth of blood vessels into tumors. Blood vessels carry oxygen and nutrients to the cells in the tumor. Some doctors currently use angiogenesis blockers, such as the anti-cancer drug Avastin, to inhibit the signal. Without blood vessels, tumors suffocate and starve. As opposed to toxic drugs that poison and kill cancer cells, Pepper said these new types of anti-cancer drugs will stay potent longer. "The basic point I'm making is in order to save the patient, we don't have to have a drug that kills the cancer cells," Pepper said. If drug development continues to focus on killing individual cells, he said, "We're always going to keep running on the same treadmill. "We're going to be in this situation where we desperately need a new antibiotic by tomorrow, or maybe by yesterday," Pepper said. "That's not going to be a temporary emergency -- it's going to be a permanent emergency, unless we take a new approach." University of Arizona |
|||||||||||||||||||||
| Related Cancer Cells Current Events and Cancer Cells News Articles Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Taking aim at mysterious DNA structures in the battle against cancer Designers of anti-cancer drugs are aiming their arrows at mysterious chunks of the genetic material DNA that may play a key role in preventing the growth and spread of cancer cells, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. Experimental agent reduces breast cancer metastasis to bone Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer. Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone. Study reveals a 'missing link' in immune response to disease The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery. Discovery offers potential new pancreatic cancer treatment Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. Early-stage, HER2-positive breast cancer patients at increased risk of recurrence Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. A Potential Anti-cancer Agent Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. More Cancer Cells Current Events and Cancer Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||